FedCircuitBlog

Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:

• an article about a bill that “would stop pharma companies from using lawsuits to block the sale of a competing generic drug”;
• another article about a party “ask[ing] the US Supreme Court to clarify its rule for when an idea is considered abstract and thus not eligible to be patented”; and
• a blog post about “U.S. Patent and Trademark Office (USPTO) Director Kathi Vidal . . . correcting the Patent Trial and Appeal Board (PTAB) on its approach to the ‘compelling merits’ analysis.”

Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:

• a blog post about a Federal Circuit decision “clarifying the requirements for the disclosure of technology that is ready for patenting at a public event to qualify as being ‘in public use’”;
• an article about a Federal Circuit ruling finding “federal workers are generally not entitled to extra pay for being exposed to COVID-19 through their jobs”; and
• another article about the ramifications of “US Patent and Trademark Office Director Kathi Vidal’s reinstatement of two companies she’d removed from high-profile [inter partes review] patent challenges.”

Here is a report on recent news and commentary related to the Federal Circuit and its cases. Today’s report highlights:

• an article about a “multibillion-dollar patent infringement case at the Federal Circuit”;
• another article about the declining number of Delaware patent filings; and
• a blog post about the Director of the U.S. Patent and Trademark Office issuing sanctions based on abuse of the inter partes review process.